Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 6, 2019Frontiers in ImmunologyOpen Access

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

View Full Paper
Ask AI
Bookmark
Share

Authors

CKCeline KaegiUniversity Hospital of ZurichBWBenjamin WuestUniversity Hospital of ZurichJSJens SchreinerUniversity Hospital of Basel

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kaegi et al. (2019) studied this question.

synapsesocial.com/papers/6a1730865498a92aabbde4efhttps://doi.org/10.3389/fimmu.2019.01990
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Successful treatment of refractory generalized myasthenia gravis with rituximab2008 · 106 citations
  2. 2Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT2018 · 100 citations
  3. 3Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement2009 · 83,708 citations
  4. 4A pilot open‐label phase II trial of rituximab for non‐criteria manifestations of antiphospholipid syndrome2012 · 277 citations
  5. 5Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial2017 · 34 citations